Abivax (ABVX) Enterprise Value (2021 - 2026)

Abivax's Enterprise Value history runs 6 years deep, the most recent figure standing at -$584.7 million for Q1 2026.

• On a quarterly basis, Enterprise Value fell 400.34% year-over-year to -$584.7 million in Q1 2026; TTM through Mar 2026 was -$584.7 million, a 400.34% decrease from a year earlier, with the FY2025 full-year figure at -$626.4 million, down 281.35% from the prior year.
• Enterprise Value advanced to -$584.7 million in Q1 2026 per ABVX's latest filing, from -$626.4 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$27.5 million in Q4 2022 and bottomed at -$700.1 million in Q3 2025.
• The 5-year median for Enterprise Value is -$253.2 million (2024), against an average of -$314.4 million.
• Across the five-year window, Enterprise Value plunged 921.83% in 2023 and jumped 69.17% in 2025, its largest moves.
• Year by year, Enterprise Value stood at -$27.5 million in 2022, then plunged by 921.83% to -$281.0 million in 2023, then jumped by 42.28% to -$162.2 million in 2024, then slumped by 286.26% to -$626.4 million in 2025, then rose by 6.65% to -$584.7 million in 2026.
• Per Business Quant, the three latest ABVX Enterprise Value figures stand at -$584.7 million (Q1 2026), -$626.4 million (Q4 2025), and -$700.1 million (Q3 2025).